Gilead confirms plan to file filgotinib this year – Trust favourite Gilead (NASDAQ: GILD) announced yesterday that it expected to file its closely watched JAK1 inhibitor filgotinib – which is licensed from the Belgian biotech Galapagos (NASDAQ:GLPG) – in the key indication of rheumatoid arthritis (RA) later this year, up to 12 months ahead of the […]
Incyte details positive outcome of topical rux in vitiligo Trust favourite Incyte (Nasdaq:INCY) saw its stock rise by 5% today after reporting positive results of a Phase II study of ruxolitinib cream in the treatment of vitiligo (a condition characterised by de-pigmentation of skin) at a scientific conference over the weekend. Incyte, which is held by […]
Trust favourite Array acquired by Pfizer US cancer focussed biotech Array BioPharma (NASDAQ: ARRY) has accepted a $48 per share cash takeover offer from Pfizer, a 62% premium of its closing price on Friday and equivalent to an enterprise value of $11.4bn (market cap less net cash). Array, whose stock rose by 56% this morning, […]
Genmab finally sets sights on Nasdaq Denmark’s Genmab, which has the distinction of being Europe’s largest biotech by market cap (DKK71.9bn/$10.7bn) and has filed with the US SEC to raise $500m through a US IPO of American depositary shares (ADS) on Nasdaq. The move is notable both for the proposed offering’s size as well as […]
Economic & Political Roundup A collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell any of the […]
Quarterly Investment Companies Roundup – First Quarter 2019 QuotedData news Through the first quarter of 2019, global equities largely clawed back the losses suffered over the final weeks of 2018. How much longer this ten-year bull market can sustain itself is the subject of much debate. US interest rate rises have stalled, reflecting growing cautiousness. Elsewhere, […]
Biogen Alzheimer’s failure drags down Biotech Growth – Biogen, a key holding in Biotech Growth Trust and a component of most other biotech and healthcare portfolios, has lost a third of its value after trials of an Alzheimer’s drug failed to show any benefit. Biogen and its partner, Japanese drugmaker Eisai, said they would stop […]
Sponsors A number of fund management houses have kindly sponsored our guides, monthly, quarterly and annual publications including: Abrdn, Allianz, Baillie Gifford, Fidelity, Jupiter, Martin Currie and Polar Capital Research clients Here is a list of the clients that Marten & Co has been paid to publish research on: Aberdeen Emerging Markets (now abrdn China) Aberdeen Frontier Markets, abrdn European Logistics Income […]
IBT adds to Celgene, reduces Neurocrine in July rejig International Biotechnology Trust (IBT) appears to have boosted its shareholding in Celgene – which has risen by one place and ~ two NAV percentage points to become its top investee company, as part of a rejig of its largest investments in July. According to the trust’s latest […]
FDA sets Feb target review date for IBT-backed Stemline Therapeutics The US FDA has accepted Stemline Therapeutics (Nasdaq:STML)’s filing for Elzonris (tagraxofusp) for review for blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare haematological cancer, and with priority review, the agency has set itself a PDUFA target action date of 21 February 2019 – although […]
